Floatz logo

Pumvc3-Igfbp2-Her2-Igf1R Plasmid Dna Vaccine

Breast Cancer

University of WashingtonvaccinePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

890 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Darolutamide
Vandana Abramson
Phase 2BBB
Palbociclib
Hoffmann-La Roche
Phase 4BB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Ribociclib
National Cancer Institute (NCI)
Phase 4BB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Pumvc3-Igfbp2-Her2-Igf1R Plasmid Dna Vaccine is also rated in:

No Evidence of DiseaseDormant
CC
Indicative ·
47 / 100
View asset →
One or More Positive Axillary NodesDormant
CC
Indicative ·
47 / 100
View asset →
breast carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →